GlassScriptPhysician profile
Brianna Gedeon
NPI 1457931727
$3,295.69
in general payments reported to CMS, 2019-2025
30 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.87 · 2022: $261 · 2023: $67.60 · 2024: $840 · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $530.27 | 2024-2025 | Airsupra, Breztri |
| Axsome Therapeutics, INC. | $347.74 | 2024-2025 | Auvelity, Symbravo |
| Abbvie INC. | $339.12 | 2022-2025 | |
| Corcept Therapeutics | $259.80 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $233.60 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $221.03 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $183.29 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $177.00 | 2025 | Rexulti, Vyepti |
| Novo Nordisk INC | $166.73 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $156.05 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $66.37 | 2022 | |
| Azurity Pharmaceuticals, INC. | $57.90 | 2023-2024 | Edarbyclor, Edarbyclor |
| Pfizer INC. | $56.89 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.37 | 2024-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $42.70 | 2025 | Spravato |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $40.22 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $39.69 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $36.72 | 2022 | |
| Esperion Therapeutics, INC. | $33.86 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $33.31 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $31.98 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $31.49 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $30.00 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $26.08 | 2024 | |
| Inspire Medical Systems, INC. | $22.13 | 2024 | Inspire |
| Amgen INC. | $21.11 | 2025 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $16.25 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $14.32 | 2025 | |
| Nestle Healthcare Nutrition INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Gedeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.